Ποια είναι η τιμή για Bristol-Myers Squibb Company (BMY)

Η τιμή για Bristol-Myers Squibb Company (BMY) είναι $62.26

Ποια είναι η κεφαλαιοποίηση αγοράς για Bristol-Myers Squibb Company (BMY)

Η κεφαλαιοποίηση αγοράς για Bristol-Myers Squibb Company (BMY) είναι $127.18B

Bristol-Myers Squibb Company (BMY) Διαίρεση Μετοχών

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Έτος	Διάσπαση	Πολλαπλασιαστής	Αθροιστικός Πολλαπλασιαστής
2001-08-07	1000000:951777	x1.0506662800215	x33.621320960687
1999-03-01	2:1	x2	x32
1997-03-03	2:1	x2	x16
1987-06-10	2:1	x2	x8
1983-05-27	2:1	x2	x4
1977-05-31	2:1	x2	x2

Έτος

Διάσπαση

Πολλαπλασιαστής

Αθροιστικός Πολλαπλασιαστής

2001-08-07

1000000:951777

x1.0506662800215

x33.621320960687

1999-03-01

2:1

x32

1997-03-03

2:1

x16

1987-06-10

2:1

1983-05-27

2:1

1977-05-31

2:1

Εταιρεία	Αριθμός διασπάσεων μετοχών	Αθροιστικός Πολλαπλασιαστής	Χώρα
Eli Lilly and Company LLY.US	4	x15	US
Johnson & Johnson JNJ.US	7	x432	US
AbbVie Inc. ABBV.US	0	-	US
Roche Holding AG RO.SW	2	x10000	CH
Merck & Co., Inc. MRK.US	7	x226	US

Εταιρεία

Αριθμός διασπάσεων μετοχών

Αθροιστικός Πολλαπλασιαστής

Χώρα